These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8190667)

  • 21. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
    Maxeiner HG; Keulen W; Schuurman R; Bijen M; de Graaf L; van Wijk A; Back N; Kline MW; Boucher CA; Nijhuis M
    J Infect Dis; 2002 Apr; 185(8):1070-6. PubMed ID: 11930317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use.
    Mattson RH
    Rev Neurol Dis; 2004; 1 Suppl 1():S10-7. PubMed ID: 16400290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AZT delta study: major European/Australian study finds combinations better than AZT alone.
    King E
    AIDS Treat News; 1995 Oct; (no 232):3-4. PubMed ID: 11362876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.
    Hwang SW; Leo YS
    Singapore Med J; 2001 Jun; 42(6):247-51. PubMed ID: 11547960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
    Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin MA; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
    Antivir Ther; 2001 Sep; 6(3):179-83. PubMed ID: 11808752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
    J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
    Walker UA; Bäuerle J; Laguno M; Murillas J; Mauss S; Schmutz G; Setzer B; Miquel R; Gatell JM; Mallolas J
    Hepatology; 2004 Feb; 39(2):311-7. PubMed ID: 14767983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DdI for AIDS patients intolerant to AZT.
    Am Pharm; 1991 Dec; NS31(12):10. PubMed ID: 1763769
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA triple header. Food and Drug Administration.
    Smart T
    GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining d4T/ddI looks promising.
    Posit Aware; 1996; 7(1):7. PubMed ID: 11363129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.
    Monpoux F; Sirvent N; Cottalorda J; Mariani R; Lefbvre JC
    AIDS; 1997 Oct; 11(12):1523-5. PubMed ID: 9342078
    [No Abstract]   [Full Text] [Related]  

  • 35. Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?
    Castelnuovo B; Nanyonjo A; Kamya M; Ocama P
    Afr Health Sci; 2008 Jun; 8(2):133-4. PubMed ID: 19357764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AIDS treatment: 'parallel trick' for ddI.
    McGourty C
    Nature; 1989 Oct; 341(6242):474. PubMed ID: 2507927
    [No Abstract]   [Full Text] [Related]  

  • 37. Continued zidovudine or didanosine for human immunodeficiency virus infection.
    Saitz R; Friedmann PD; Roberts MS
    N Engl J Med; 1992 Nov; 327(22):1598; author reply 1599. PubMed ID: 1435891
    [No Abstract]   [Full Text] [Related]  

  • 38. Dose of doubt.
    Day M
    Nurs Times; 1994 Jul 13-19; 90(28):20. PubMed ID: 8065956
    [No Abstract]   [Full Text] [Related]  

  • 39. [Striated nail discoloration caused by zidovudine].
    Bendick C; Rasokat H; Steigleder GK
    Z Hautkr; 1989 Feb; 64(2):91-5. PubMed ID: 2718548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stavudine (d4T) for HIV.
    Am Pharm; 1994 Aug; NS34(8):9. PubMed ID: 7942505
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.